Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial

Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)

October 16, 2024 6:02 AM EDT

Goldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "While AMGN continues to execute through a catalyst-rich year, the focus remains on key upcoming Ph2 obesity data for MariTide (GLP1-R agonistAn agonist is a drug that binds to a receptor and amplifies its intended effect./GIPR antagonist), expected by YE24, where positive results could unlock access to the obesity mega-TAM... More